Literature DB >> 29253321

Role of capsule endoscopy in alarm features and non-responsive celiac disease: A European multicenter study.

Enrique Perez-Cuadrado-Robles1, Marisol Lujan-Sanchis2, Luca Elli3, Jose-Francisco Juanmartinena-Fernandez4, Javier Garcıa-Lledo5, Lucıa Ruano-Dıaz6, Juan Egea-Valenzuela7, Victoria-Alejandra Jimenez-Garcıa8, Federico Arguelles-Arias8, Mileidis San Juan-Acosta9, Cristina Carretero-Ribon10, Noelia Alonso-Lazaro11, Bruno Rosa12, Francisco Sanchez-Ceballos13, Antonio Lopez-Higueras2, Ignacio Fernandez-Urien-Sainz4, Federica Branchi3, Julio Valle-Muñoz6, Pilar Borque-Barrera9, Santiago Gonzalez-Vazquez10, Vicente Pons-Beltran11, Sofıa Xavier12, Begona Gonzalez-Suarez14, Juan-Manuel Herrerıas-Gutierrez8, Enrique Perez-Cuadrado-Martınez2, Javier Sempere-Garcıa-Arguelles1.   

Abstract

BACKGROUND AND AIM: The role of capsule endoscopy (CE) in established celiac disease (CD) remains unclear. Our objective was to analyze the usefulness of CE in the suspicion of complicated CD.
METHODS: This was a retrospective multicenter study. One hundred and eighty-nine celiac patients (mean age: 46.6 ± 16.6, 30.2% males) who underwent CE for alarm symptoms (n = 86, 45.5%) or non-responsive CD (n = 103, 54.5%) were included. Diagnostic yield (DY), therapeutic impact and safety were analyzed.
RESULTS: Capsule endoscopy was completed in 95.2% of patients (small bowel transit time: 270.5 ± 100.2 min). Global DY was 67.2%, detecting atrophic mucosa (n = 92, 48.7%), ulcerative jejunoileitis (n = 21, 11.1%), intestinal lymphoma (n = 7, 3.7%) and other enteropathies (n = 7, 3.7%, six Crohn's disease cases and one neuroendocrine tumor). The DY of CE was significantly higher in patients presenting with non-responsive disease compared to patients with alarm symptoms (73.8% vs 59.3%, P = 0.035). The new findings of the CE modified management in 59.3% of the cases. There were no major complications.
CONCLUSION: Capsule endoscopy may be a moderately helpful and safe diagnostic tool in the suspicion of complicated CD, modifying the clinical course of these patients.
© 2018 Japan Gastroenterological Endoscopy Society.

Entities:  

Keywords:  capsule endoscopy; celiac disease; gluten; lymphoma; non-responsive celiac disease

Mesh:

Year:  2018        PMID: 29253321     DOI: 10.1111/den.13002

Source DB:  PubMed          Journal:  Dig Endosc        ISSN: 0915-5635            Impact factor:   7.559


  4 in total

Review 1.  The global burden of coeliac disease: opportunities and challenges.

Authors:  Govind K Makharia; Prashant Singh; Carlo Catassi; David S Sanders; Daniel Leffler; Raja Affendi Raja Ali; Julio C Bai
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-03       Impact factor: 46.802

2.  Adherence to dietary treatment and clinical factors associated with anti-transglutaminase antibodies in celiac disease during the follow-up.

Authors:  Marta Miró; Manuel Alonso-Garrido; Manuel Lozano; Juanjo Peiró; Lara Manyes
Journal:  Heliyon       Date:  2021-04-01

3.  Nomenclature and Definition of Atrophic Lesions in Small Bowel Capsule Endoscopy: A Delphi Consensus Statement of the International CApsule endoscopy REsearch (I-CARE) Group.

Authors:  Luca Elli; Beatrice Marinoni; Reena Sidhu; Christian Bojarski; Federica Branchi; Gian Eugenio Tontini; Stefania Chetcuti Zammit; Sherine Khater; Rami Eliakim; Emanuele Rondonotti; Jean Cristhophe Saurin; Mauro Bruno; Juliane Buchkremer; Sergio Cadoni; Flaminia Cavallaro; Xavier Dray; Pierre Ellul; Ignacio Fernandez Urien; Martin Keuchel; Uri Kopylov; Anastasios Koulaouzidis; Romain Leenhardt; Peter Baltes; Hanneke Beaumont; Clelia Marmo; Deirdre McNamara; Alessandro Mussetto; Artur Nemeth; Enrique Perez Cuadrado Robles; Guillame Perrod; Gabriel Rahmi; Maria Elena Riccioni; Alexander Robertson; Cristiano Spada; Ervin Toth; Konstantinos Triantafyllou; Gabriele Wurm Johansson; Alessandro Rimondi
Journal:  Diagnostics (Basel)       Date:  2022-07-13

4.  Celiac Disease Diagnosed after Gastrectomy for Gastric Cancer.

Authors:  Maho Iwamoto; Kimitoshi Kato; Yoshiaki Kusumi; Shinobu Masuda; Tomohiro Nakayama; Mitsuhiko Moriyama
Journal:  Intern Med       Date:  2021-07-30       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.